Tech27 Agu 2026
FDA Clears Groundbreaking Pancreatic Cancer Drug After Decades of Elusive KRAS Targets
The Food and Drug Administration has granted expedited approval to daraxonrasib, sold under the brand name Rasonque, for adults with metastatic pancreatic cancer. In clinical trials, the once-daily pill nearly doubled median overall survival compared to standard chemotherapy by targeting previously undruggable RAS proteins. While the clearance represents a major clinical milestone, patient advocates and clinicians note that high list prices and drug resistance pose significant ongoing challenges.
By NeuraFeed